SCHEMBL1402010

SCHEMBL1402010

CC(C)n1cnc(CCNc2nc(NCC(c3ccccc3)c3ccccc3)c3ncn([C@@H]4C[C@H](NC(=O)C5CC5)[C@@H](O)[C@H]4OC(=O)C(F)(F)F)c3n2)c1

nearest known ligand 0.81

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 20/20 0.81
ADORA3 P0DMS8 9/20 0.81
ADORA2B P29275 2/20 0.44
ADORA1 P30542 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1402066 0.98 ADORA2A (0.81) ADORA2AADORA3ADORA2BADORA1
SCHEMBL1401985 0.93 ADORA2A (0.81) ADORA2AADORA3ADORA2BADORA1
SCHEMBL1402022 0.92 ADORA2A (0.81) ADORA2AADORA3ADORA2BADORA1
SCHEMBL1402074 0.91 ADORA2A (0.81) ADORA2AADORA3ADORA2BADORA1
SCHEMBL4224393 0.89 ADORA2A (0.67) ADORA2AADORA3ADORA2BADORA1
SCHEMBL4224242 0.89 ADORA2A (0.67) ADORA2AADORA3ADORA2BADORA1
SCHEMBL1401980 0.87 ADORA2A (0.81) ADORA2AADORA3ADORA2BADORA1
SCHEMBL589495 0.86 ADORA2A (0.65) ADORA2AADORA3ADORA2BADORA1
SCHEMBL4224251 0.85 ADORA2A (0.90) ADORA2AADORA3ADORA2BADORA1
SCHEMBL1402024 0.85 ADORA2A (0.82) ADORA2AADORA3ADORA2BADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163754-B2 inflammatory or obstructive airways diseases; in combination with an antiinflammatory, bronchodilatory, antihistamine or anti-tussive; N-[4-(6-Amino-2-phenethylamino-purin-9-yl)-2,3-dihydroxy-cyclopentyl]-propionamide NOVARTIS AG (CH) 2012-04-24 US disclosed
EP-2292619-A1 Purine derivatives for use as adenonsin A-2A receptor agonists Novartis AG (CH) 2011-03-09 EP disclosed